Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating first-line sintilimab plus apatinib and S-1 with oxaliplatin (SOX) in AFP-producing gastric or gastroesoph…
-
CLINICAL_TRIALS trial_result · 2025-06-08Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers [Phase 1]
Phase 1 trial updating on the addition of Adavosertib to radiation therapy in patients with incurable esophageal and gastroesophageal juncti…
-
CLINICAL_TRIALS withdrawal · 2025-06-08Clinical Trial Update: Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
A clinical trial evaluating circulating tumor DNA in locally advanced esophageal and gastroesophageal junction adenocarcinoma has been withd…
-
FDA approval · 2025-06-06FDA Approved: VYLOY — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for VYLOY (zolbetuximab) from Astellas Pharma US, expanding/updating its labeling.
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
A completed neoadjuvant trial comparing nivolumab plus SOX versus nivolumab plus FLOT in HER2-negative gastric and gastroesophageal junction…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection [Phase 1, Phase 2]
This update describes an ongoing Phase 1/2 clinical trial evaluating CT041 autologous CAR T-cell therapy for gastric adenocarcinoma, gastroe…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery [Phase 1, Phase 2]
This update covers a Phase 1/2 trial of olaparib plus ramucirumab in patients with metastatic or locally recurrent gastric or gastroesophage…
-
CLINICAL_TRIALS research · 2025-06-02Clinical Trial Update: Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma [Phase 2, Phase 3]
This clinical trial update outlines a Phase 2/Phase 3 study evaluating the timing of minimally invasive local treatment following first-line…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
This clinical trial update discusses how perioperative treatment efficacy may be influenced by the tumor microenvironment in locally advance…
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery [Phase 1]
Phase 1 trial evaluating the addition of Telomelysin to chemoradiation for patients with advanced esophageal or gastroesophageal junction ad…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ [Phase 2]
Phase 2 clinical trial evaluating Adebrelimab in combination with chemoradiotherapy and surgery for gastroesophageal junction and gastric ad…
-
CLINICAL_TRIALS research · 2025-05-16Clinical Trial Update: Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression [Phase 2, Phase 3]
A clinical trial update describing a Phase 2/3 study evaluating Fruquintinib plus Sintilimab and SBRT for second-line or higher treatment of…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
A completed clinical trial evaluating PET imaging with the radiotracer 18F-BMS-986229 in patients with cancers of the esophagus, stomach, or…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) [Phase 2]
Phase 2 study evaluating IMU-131 (HER-Vaxx) with chemotherapy or pembrolizumab in metastatic HER2-overexpressing gastric cancer; the trial w…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer [Phase 2, Phase 3]
A Phase 2/Phase 3 trial is evaluating total neoadjuvant FLOT chemotherapy for locally advanced gastric and gastroesophageal junction cancer;…
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]
Phase 2 study evaluating a combination of QLS31905, QL2107, and chemotherapy as first-line therapy for CLDN18.2-positive unresectable locall…
-
CLINICAL_TRIALS research · 2025-04-25Clinical Trial Update: A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]
Phase 3 clinical trial update evaluating disitamab vedotin plus tislelizumab and chemotherapy versus tislelizumab and chemotherapy in HER2-l…
-
CLINICAL_TRIALS research · 2025-04-22Clinical Trial Update: Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 3]
This Phase 3 clinical trial assesses whether adding apatinib to sintilimab and perioperative SOX improves outcomes versus sintilimab plus pe…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma [Phase 2]
Phase II trial evaluating Iparomlimab/Tuvonralimab (QL1706) with XELOX in HER2-negative, low PD-L1 expressing unresectable or metastatic gas…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma [NA]
Clinical trial OPPOSITE, studying outcome prediction of systemic treatment in esophagogastric carcinoma, has completed. The sponsor is Unive…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer [Phase 1, Phase 2]
Clinical trial update on Vactosertib combined with pembrolizumab for metastatic colorectal cancer and gastric/gastroesophageal junction aden…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer [Phase 2]
Phase 2 trial update evaluating fruquintinib in combination with a PD-1 inhibitor as first-line maintenance therapy for advanced gastric can…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) [Phase 3]
Phase 3 trial MK-3475-811/KEYNOTE-811 evaluating pembrolizumab plus placebo with trastuzumab and chemotherapy in HER2-positive advanced gast…
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1]
Phase 1 trial evaluating SL-279252, a PD-1-Fc-OX40L fusion protein, in adults with advanced solid tumors or lymphomas has been completed wit…
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial [Phase 2]
Phase 2 trial (NCT04510064) evaluated camrelizumab combined with nab-POF chemotherapy in patients with initially unresectable locally advanc…